This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.
Barclays Sticks to Its Buy Rating for CVS Health (CVS)
Barclays analyst Andrew Mok CFA maintained a Buy rating on CVS Health today and set a price target of $93.00.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
According to TipRanks, Mok CFA is an analyst with an average return of -1.9% and a 48.02% success rate. Mok CFA covers the Healthcare sector, focusing on stocks such as Brookdale Senior Living, Humana, and Acadia Healthcare.
CVS Health has an analyst consensus of Strong Buy, with a price target consensus of $96.14.
Based on CVS Health’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $105.69 billion and a net profit of $2.94 billion. In comparison, last year the company earned a revenue of $97.71 billion and had a net profit of $1.64 billion
Read More on CVS:
This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
